Navigation Links
Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
Date:5/5/2008

Retrospective Chart Review in 10 Geographic Regions throughout the United States Presented at Pediatric Academic Societies (PAS) Annual Meeting

HONOLULU, May 5 /PRNewswire/ -- MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of Synagis(R) (palivizumab) as a preventive measure against respiratory syncytial virus (RSV) disease in high-risk infants. RSV is a leading cause of viral respiratory infection among preterm infants.

Approximately 4,000 medical records from premature infants born at 32-to-35 weeks gestational age were reviewed. Fifty percent of those infants received Synagis. RSV prophylaxis was requested, but not administered in about one quarter of these infants. This group was found to have an RSV hospitalization rate of 8.3 percent, which was almost three times the rate of RSV hospitalization among those infants whose physicians did not request RSV prophylaxis (2.9 percent).

"These data support our position that pediatricians should have the final say in the diagnosis and care of their high-risk patients," said Jessie Groothuis, M.D., lead author of the study and MedImmune vice president, medical and scientific affairs, infectious disease. "Our findings indicate that after nearly 10 years of use of Synagis, the clinical judgment and experience of physicians serve to identify infants at high risk of RSV hospitalization, and should be relied upon to ensure patients get proper care."

This retrospective chart review, conducted in 10 geographic regions across the United States, included 376 physicians from 2005 to 2006. Data were presented at a poster session at the Pediatric Academic Societies (PAS) Annual Meeting being held this week in Honolulu, HI.

About Synagis

Synagis (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
2. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
3. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nov. 8, 2011 MedBox (Pink Sheets: ... have changed their ticker symbol to MDBX.  The company ... to MedBox. The company is a ... dispensing systems of prescription medicines. The free-standing unit features ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: European Markets ... http://www.reportlinker.com/p0681077/European-Markets-for-Ophthalmic-Devices-2011-Diagnostic--Invasive.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Ophthalmic_Devices ... interventional ophthalmic device market was valued at ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 2European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 3European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 4European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 5European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 6European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 7European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 8European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 9European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 10European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 11European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 12European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 13European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 14European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 15European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 16European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 17European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 18European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 19European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 20European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 21
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
(Date:4/17/2014)... they suffer a cardiac arrest outside of a hospital ... to new research conducted at St. Michael,s Hospital. , ... arrest get adrenaline, which has been the drug recommended ... Lin, an emergency physician and trauma team leader at ... survival rates of patients who suffer a cardiac outside ...
(Date:4/17/2014)... have called for more research to be carried ... in sub-Saharan Africa. In a paper in ... Stothard, working with colleagues in the department of ... in Cleveland Ohio, University of Cambridge and the ... the joint burden of HIV/AIDS and schistosomiasis of ...
(Date:4/16/2014)... (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) ... study of CDX-1401 in solid tumors, including long-term patient ... (Vol 6 Issue 232). The data demonstrate robust ... benefit in patients with very advanced cancers and suggest ...
(Date:4/16/2014)... it is well known that fertility treatments are the ... multiples are at elevated risk of premature birth, these ... Fertility and Sterility . The article identifies ... the odds of multiple births and prematurity, including expanding ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... maintain safe driving habits starts at home with open ... past Liberty Mutual/SADD research, teens of parents who establish ... are less likely to drive under the influence of ... percent vs. 56 percent) than those without set consequences. ...
... Bermuda, Oct. 19 Allied World,Assurance Company Holdings, Ltd ... Susan Chmieleski, Senior Vice President, Healthcare Product & Risk,Management, ... and Risk,Management (ASHRM) annual conference in Denver, Colorado on ... Does Your Risk Program,Work?, , ...
... researchers say , MONDAY, Oct. 19 (HealthDay News) -- ... disease (IBD) increases the risk of cancers related to ... includes Crohn,s disease and ulcerative colitis. Thiopurine drugs are ... maintain remission in IBD patients. , For this study, ...
... 19 According to Google Trends ( www.google.com/trends/hottrends?q=the+cookie+diet&date=2009-10-16&sa=X ... ranking of the 40 most-searched terms on the Google ... sixth most-searched term last Friday. The highest ranking term ... boy throws up" which ranked a distant fifteenth. ...
... year of life, nutrition is critical to establishing a foundation ... time, a collection of visual images that tell the story ... growth and development during that critical first twelve months will ... go to: http://multivu.prnewswire.com/mnr/enfamil/40064/ , This ...
... ... for healthcare claims in response to the skyrocketing overpayment recoupment dispute and ... hospitals were told by insurance Co.,s and payers, on every EOB, to ... providers knew how to, as there has been very little resource available ...
Cached Medicine News:Health News:Liberty Mutual Teen Driving Website Offers New Family Communication Tools to Promote Driving Safety 2Health News:Liberty Mutual Teen Driving Website Offers New Family Communication Tools to Promote Driving Safety 3Health News:Allied World's Susan Chmieleski to Speak at American Society for Healthcare Risk Management (ASHRM) Annual Conference and Exhibition 2Health News:Allied World's Susan Chmieleski to Speak at American Society for Healthcare Risk Management (ASHRM) Annual Conference and Exhibition 3Health News:Drugs for Irritable Bowel Might Increase Cancer Risk 2Health News:Dr. Siegal's Cookie Diet Beats 'Balloon Boy' Story on Google's Most-Searched Topics List 2Health News:Dr. Siegal's Cookie Diet Beats 'Balloon Boy' Story on Google's Most-Searched Topics List 3Health News:Photos: First-of-Its-Kind Website Unveiled at 'Modern Moms Meet Modern Science' Meeting 2Health News:ERISAclaim.com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the $6 Trillion Healthcare Denial Management Market 2Health News:ERISAclaim.com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the $6 Trillion Healthcare Denial Management Market 3Health News:ERISAclaim.com Announced Free ERISA Webinar for Healthcare Overpayment Dispute and Claim Denials in Response to Increasing High Demand from the $6 Trillion Healthcare Denial Management Market 4
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
Steroid eluting pacemaker leads with preformed J...
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: